D.E. Shaw & Co
EGRX

D.E. Shaw & Co’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

D.E. Shaw & Co’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,600
Closed -$400K – 3934
2018
Q1 		$400K Sell
7,600
-400
-5% -$23.3K ﹤0.01% 2994
2017
Q4 		$427K Buy
+8,000
New +$445K ﹤0.01% 3066
2015
Q4 		– Sell
-30,000
Closed -$2.22M – 4008
2015
Q3 		$2.22M Buy
30,000
+20,000
+200% +$1.66M ﹤0.01% 2021
2015
Q2 		$809K Buy
+10,000
New +$651K ﹤0.01% 2849

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

D.E. Shaw & Co's EGRX Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 54,625 shares — an estimated $204K sold.

D.E. Shaw & Co first reported a position in EGRX in Q3 2014 and held it in 34 quarters. The position peaked at $11.5M in Q4 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • D.E. Shaw & Co reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 54,625 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $204K.
  • D.E. Shaw & Co first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2014 and held it in 34 quarters.
  • D.E. Shaw & Co's Eagle Pharmaceuticals, Inc. position peaked at $11.5M in Q4 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.